Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These…
| Price | $8.19 |
|---|---|
| Market cap | $796.33M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NASDAQ |
| 52-week range | 3.3-11.055 |
| Beta | 0.73 |
Explore AVR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.